Quick Take
Silk Road Medical (SILK) intends to raise $75 million in an IPO of its common stock, per an amended registration statement.
The company sells a transcarotid artery stenting device in the U.S.
SILK is growing rapidly in the U.S., has strong growth prospects internationally with its CE Mark approval in Europe, and investors are supporting the IPO, so it is one to watch closely.
Company & Technology
Sunnyvale, California-based Silk Road Medical was founded in 2007 to develop an effective treatment to reduce the probability of a stroke by creating